Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced dose Efavirenz in HIV-infected individuals (Encore1 PK sub-study)
NCT01271894Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Sep 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Started Sep 2011; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01271894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271894.